Clinical Trials in Arkansas

Browse 99 Arkansas Medical Studies Across 974 Cities
60 Phase 3 Trial · 5868 Arkansas Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Clinical Trials in Arkansas

Reviewed by Michael Gill, B. Sc.

Image of Sutter Auburn Faith Hospital in Auburn, United States.

10 Arkansas Clinical Trials Near Me

Top Cities for Arkansas Clinical Trials

Miami

107Active Trials

University of Miami Miller School of Medicine-Sylvester Cancer CenterTop Active Site

Los Angeles

91Active Trials

Children's Hospital Los AngelesTop Active Site

Arkansas Clinical Trials by Phase of Trial

N/A Arkansas Clinical Trials

10Active Arkansas Clinical Trials

9Number of Unique Treatments

289Number of Active Locations

Partially hydrolyzed protein infant formula SCD + CKRT Arm Treatment Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download Treatment HIV D+/R+Diet and Exercise TCM plus COPES Oral Nutritional Supplement Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®

Most Recent Arkansas Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

Arm 3: Livmoniplimab Dose B + Budigalimab for Liver Cancer

9/21/2023

Phase 2

Povorcitinib Dose A for Angioedema

7/31/2023

Phase 2

Upadacitinib for Rheumatoid Arthritis

6/15/2023

Phase 3

Ruxolitinib 1.5% Cream for Prurigo Nodularis

6/12/2023

Phase 3

Arm III (DRd-DR): for Multiple Myeloma

6/1/2023

Phase 3

About The Author

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: September 28th, 2023

References¹ Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/31401903² Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. https://pubmed.ncbi.nlm.nih.gov/31401903³ ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669. https://pubmed.ncbi.nlm.nih.gov/22797452⁴ Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10. doi: 10.1007/BF01709751. No abstract available. https://pubmed.ncbi.nlm.nih.gov/8844239⁵ Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84. doi: 10.1159/000339789. Epub 2012 Aug 7. No abstract available. https://pubmed.ncbi.nlm.nih.gov/22890468⁶ Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005 Aug 17;294(7):813-8. doi: 10.1001/jama.294.7.813. https://pubmed.ncbi.nlm.nih.gov/16106006⁷ Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. https://pubmed.ncbi.nlm.nih.gov/25014687⁸ Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. https://pubmed.ncbi.nlm.nih.gov/19704057⁹ Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. https://pubmed.ncbi.nlm.nih.gov/19704057¹⁰ Self WH, Semler MW, Wanderer JP, Wang L, Byrne DW, Collins SP, Slovis CM, Lindsell CJ, Ehrenfeld JM, Siew ED, Shaw AD, Bernard GR, Rice TW; SALT-ED Investigators. Balanced Crystalloids versus Saline in Noncritically Ill Adults. N Engl J Med. 2018 Mar 1;378(9):819-828. doi: 10.1056/NEJMoa1711586. Epub 2018 Feb 27. https://pubmed.ncbi.nlm.nih.gov/29485926